| Literature DB >> 31188097 |
Abstract
Insurers and some drug manufacturers are turning to the Institute for Clinical and Economic Review (ICER) as the arbiter of drug prices, especially as prices soar and value is sought. But questions persist about the cost-effectiveness calculations of the Boston not-for-profit and its dependence on QALYs.Keywords: Cost-Benefit Analysis; Drug Costs; Quality-Adjusted Life Years
Mesh：
Substances：
Year: 2019 PMID： 31188097
Source DB: PubMed Journal: Manag Care ISSN： 1062-3388